We are pleased to recognize Hagens Berman partners Hannah Brennan and Abbye Klamann Ognibene for their recent appointment as interim lead class counsel in CareFirst of Maryland, Inc. et al. v. Johnson & Johnson et al. They will lead the case on behalf of health benefit providers alleging Johnson & Johnson unlawfully delayed the release of biosimilar medications that could compete with its autoimmune medication, Stelara, which has grossed more than $50 billion.